Nuclear Medicine and Biology
Volume 35, Issue 2 , Pages 227-232 , February 2008

Yttrium-86-labelled human serum albumin microspheres: relation of surface structure with in vivo stability

  • Eik Schiller

      Affiliations

    • ROTOP Pharmaka AG, Bautzner Landstraße 45, 01454 Radeberg, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +493512603461; fax: +493512603232.
    • ,
  • Ralf Bergmann

      Affiliations

    • Forschungszentrum Dresden-Rossendorf, Institute of Radiopharmacy, P.O. Box 510119, 01314 Dresden, Germany
    • ,
  • Jens Pietzsch

      Affiliations

    • Forschungszentrum Dresden-Rossendorf, Institute of Radiopharmacy, P.O. Box 510119, 01314 Dresden, Germany
    • ,
  • Bernhard Noll

      Affiliations

    • Forschungszentrum Dresden-Rossendorf, Institute of Radiopharmacy, P.O. Box 510119, 01314 Dresden, Germany
    • ,
  • Antje Sterger

      Affiliations

    • ROTOP Pharmaka AG, Bautzner Landstraße 45, 01454 Radeberg, Germany
    • ,
  • Bernd Johannsen

      Affiliations

    • ROTOP Pharmaka AG, Bautzner Landstraße 45, 01454 Radeberg, Germany
    • ,
  • Gerd Wunderlich

      Affiliations

    • Department of Nuclear Medicine, University Hospital, Fetscherstraße 74, 01307 Dresden, Germany
    • ,
  • Hans-Jürgen Pietzsch

      Affiliations

    • Forschungszentrum Dresden-Rossendorf, Institute of Radiopharmacy, P.O. Box 510119, 01314 Dresden, Germany

Received 12 September 2007 ,Revised 12 October 2007 ,Accepted 22 October 2007.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  2. Sinha VR, Goyel V, Trehan A. Radioactive microspheres in therapeutics. Pharmazie. 2004;59:419–426
  3. Nijsen JFW, van het Schip AD, Hennink WE, Rook DW, van Rijk PP, de Klerk JMH. Advances in nuclear oncology: microspheres for internal radionuclide therapy of liver tumours. Curr Med Chem. 2002;9:73–82
  4. Murthy R, Nunez R, Szklaruk J, Erwin W, Madoff DC, Gupta S, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics. 2005;25:S41–S55
  5. Ho S, Lau WY, Leung TWT, Johnson PJ. Internal radiation therapy for patients with primary or metastatic hepatic cancer. Cancer. 1998;83:1894–1907
  6. Liu MD, Uaje MB, Al-Ghazi MS, Fields D, Herman J, Kuo JV, et al. Use of Yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma. Am Surg. 2004;70:947–953
  7. Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TherSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16:1627–1639
  8. Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol. 2006;29:522–529
  9. Gray B, van Hazel G, Hope M, Burton M, Moroz P, Anderson J, et al. Randomized trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12:1711–1720
  10. van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, et al. Randomised phase 2 trial of SIR-spheres plus fluoruracil/leucovorin chemotherapy versus fluoruracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88:78–85
  11. Pöpperl G, Helmberger T, Münzing W, Schmid R, Jacobs TF, Tatsch K. Selective internal radiation therapy with SIR-spheres in patients with nonresectable liver tumors. Cancer Biother Radiopharm. 2005;20:200–208
  12. Lambert B, van de Wiele C. Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2005;32:980–989
  13. Wunderlich G, Pinkert J, Andreeff M, Stintz M, Knapp FF, Kropp J, et al. Preparation and biodistribution of rhenium-188 labeled albumin microspheres B 20: a promising new agent for radiotherapy. Appl Radiat Isot. 2000;52:63–68
  14. Wunderlich G, Drews A, Kotzerke J. A kit labeling of [188Re] human serum albumin microspheres for therapeutic use in nuclear medicine. Appl Radiat Isot. 2005;62:915–918
  15. Wunderlich G, Pinkert J, Stintz M, Kotzerke J. Labeling and biodistribution of different particle materials for radioembolization therapy with 188Re. Appl Radiat Isot. 2005;62:745–750
  16. Wagner SJ, Welch MJ. Gallium-68 labeling of albumin and albumin microspheres. J Nucl Med. 1979;20:428–433
  17. Hnatowich DJ, Schlegel P. Albumin microspheres labeled with Ga-67 by chelation: concise communication. J Nucl Med. 1981;22:623–626
  18. Lewis MR, Zhang J, Jia F, Owen N, Cutler CS, Embree MF, et al. Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice. Nucl Med Biol. 2004;31:213–223
  19. Mohsin H, Jia F, Sivaguru G, Hudson MJ, Shelton TD, Hoffman TJ, et al. Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu. Bioconjug Chem. 2006;17:485–492
  20. Patil GV. Biopolymer albumin for diagnosis and drug delivery. Drug Dev Res. 2003;58:219–247

PII: S0969-8051(07)00271-5

doi: 10.1016/j.nucmedbio.2007.10.008

Nuclear Medicine and Biology
Volume 35, Issue 2 , Pages 227-232 , February 2008

Article Tools

* Image Usage & Resolution